Most importantly, FOXC2 levels were found to be elevated in TNBCs27, 28, as well as in residual tumour cells isolated from breast cancer patients treated with conventional therapies, which were found to be enriched for mesenchymal and stem cell features12. This evidence concerns the gene FOXC2 and breast carcinoma.